Long-term outcomes in patients treated in the intensive care unit after hematopoietic stem cell transplantation

International Journal of Hematology
Makoto NakamuraYoshinobu Maeda

Abstract

The number of patients who are successfully discharged from the intensive care unit (ICU) after hematopoietic stem cell transplantation (HSCT) remains limited. Most previous studies have evaluated short-term outcomes using ICU mortality; there have been comparatively fewer reports of long-term outcomes. We retrospectively analyzed 39 HSCT patients admitted to the ICU for the first time between April 2008 and July 2014. Performance status was evaluated in four long-term survivors in July 2016. Median age at ICU admission was 54 years (range 30-68). In total, 33 patients (70.2%) required mechanical ventilation and 31 patients (66%) required dialysis. The median OS from first ICU admission was 41 days (95% confidence interval [CI]: 22-64) and the 1-year survival rate was 12.8% (95% CI 4.7-25.2). No statistically significant factors were associated with short-term outcomes. Among long-term outcomes, a second or subsequent HSCT and neutropenia at ICU admission were significant risk factors. Four of 10 ICU survivors have survived with good performance status for a median of 1994 (1203-2633) days. Our results suggest that the number of prior transplants and neutropenia at ICU admission may influence OS.

References

May 16, 2000·Critical Care Medicine·A J HuaringaR E Champlin
Apr 18, 2003·Acta Anaesthesiologica Scandinavica·K StrickerJ Takala
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A AndrykowskiJohn R Wingard
Dec 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric PèneJean-Paul Mira
Apr 28, 2006·The New England Journal of Medicine·Edward A Copelan
May 4, 2007·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Tsung-Ming YangMeng-Jer Hsieh
Jun 10, 2008·Critical Care : the Official Journal of the Critical Care Forum·Tobias M MerzHans U Rothen
Nov 26, 2010·The New England Journal of Medicine·Ted A GooleyGeorge B McDonald
Oct 3, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christopher GilbertMichael Baram
Jun 12, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elie AzoulayVirginie Lemiale
Oct 16, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ulas D BayraktarJoseph L Nates
Aug 21, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Karen EscobarPablo Ramirez
Mar 24, 2015·Bone Marrow Transplantation·E LenglinéE Azoulay

❮ Previous
Next ❯

Citations

Sep 17, 2019·Current Opinion in Critical Care·Rimda WanchooKenar D Jhaveri
Mar 14, 2019·Intensive Care Medicine·Etienne LenglinéElie Azoulay
Mar 24, 2021·Critical Care Clinics·Jaya Kala, Kevin W Finkel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.